Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of BCG Connaught vs Tice in Bladder Cancer
NCT00003779Phase 3Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Nov 1998
- Primary completion
- Jun 2001
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised trial of BCG Connaught and TICE-strain BCG in bladder cancer (2 arms), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoints: Role of prior exposition to mycobacteria for BCG treatment efficacy at 6 weeks, Yearly relapse rate at 3 years and 1 more. Started Nov 1998; status: completed.
02
Drugs
BCG ConnaughtTICE-strain BCG
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00003779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003779.